Literature DB >> 11854734

Differential gene expression in human abdominal aorta: aneurysmal versus occlusive disease.

Peter J Armstrong1, Jason M Johanning, William C Calton, Jason R Delatore, David P Franklin, David C Han, David J Carey, James R Elmore.   

Abstract

OBJECTIVE: Inflammation and atherosclerosis are present in both abdominal aortic aneurysm (AAA) and arterial occlusive disease (AOD). Changes in gene expression that underlie the development of AAA versus AOD are poorly defined. This study evaluated differences in gene expression in AAA, AOD, and control aortic tissue with human gene array technology.
METHODS: RNA was isolated from human aortic specimens (seven AAA, five AOD, and five control), and complementary DNA (cDNA) probes were generated. The cDNA probes were hybridized to a human cell interaction array of 265 genes and quantitated with phosphorimaging. The data were corrected for background and were standardized to housekeeping genes. Statistical differences in individual gene expression were determined with the Kruskal-Wallis test.
RESULTS: Of 265 genes studied, 11 showed statistically different expression in diseased aorta as compared with control. The following three genes were downregulated in AAA: collagen VI alpha1 (P <.037), glycoprotein IIIA (P <.006), and alpha2-macroglobulin (P <.020). The following two genes were upregulated in AOD: laminin alpha4 (P <.034) and insulin-like growth factor 2 receptor (P <.049). The following three genes were upregulated in both AAA and AOD: matrix metalloproteinase-9 (MMP-9; P <.005), intercellular adhesion molecule-1 (P <.012), and tumor necrosis factor--beta receptor (P <.022). The following three genes were downregulated in both AAA and AOD: integrin alpha5 (P <.012), ephrin A5 (P <.037), and rho/rac guanine nucleotide exchange factor (P <.028). Of 16 MMPs evaluated, only MMP-9 was significantly (P <.005) upregulated in both AAA and AOD. Evaluation results of four tissue inhibitors of metalloproteinases showed no significant difference in expression for all tissue types, although tissue inhibitor of metalloproteinase-1 trended toward upregulation in AAA (P =.053). Eight of the fifteen most highly expressed genes in all the groups were extracellular matrix or secreted proteins. Of these, only collagen VI alpha1 (P <.037) showed a significant change, although biglycan trended toward downregulation in AAA (P =.076).
CONCLUSION: This study used cDNA array technology in the comparison of human control and pathologic aortic tissue. Six genes had similar differential expression in both AAA and AOD as compared with control. Even more interesting were differences between AAA and AOD in the expression of five genes. These data suggest a similarity in genetic expression for both AAA and AOD, with altered expression of several genes playing a role in disease differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854734     DOI: 10.1067/mva.2002.121071

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  19 in total

1.  Suppression subtractive hybridization identifies distinctive expression markers for coronary and internal mammary arteries.

Authors:  Minghui Qin; Zhaohui Zeng; Jie Zheng; Prediman K Shah; Stephen M Schwartz; Lawrence D Adams; Behrooz G Sharifi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-30       Impact factor: 8.311

2.  The Aarskog-Scott syndrome protein Fgd1 regulates podosome formation and extracellular matrix remodeling in transforming growth factor β-stimulated aortic endothelial cells.

Authors:  Thomas Daubon; Roberto Buccione; Elisabeth Génot
Journal:  Mol Cell Biol       Date:  2011-09-12       Impact factor: 4.272

3.  Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study.

Authors:  Jane E Freedman; Martin G Larson; Kahraman Tanriverdi; Christopher J O'Donnell; Kristine Morin; Amanda S Hakanson; Ramachandran S Vasan; Andrew D Johnson; Mark D Iafrati; Emelia J Benjamin
Journal:  Circulation       Date:  2010-07-06       Impact factor: 29.690

4.  Increased Levels of Serum IL-15 and TNF-β Indicate the Progression of Human Intracranial Aneurysm.

Authors:  Shuzhe Yang; Qingyuan Liu; Junhua Yang; Jun Wu; Shuo Wang
Journal:  Front Aging Neurosci       Date:  2022-06-17       Impact factor: 5.702

Review 5.  Circulating markers of abdominal aortic aneurysm presence and progression.

Authors:  Jonathan Golledge; Philip S Tsao; Ronald L Dalman; Paul E Norman
Journal:  Circulation       Date:  2008-12-02       Impact factor: 29.690

6.  mRNA expression in rabbit experimental aneurysms: a study using gene chip microarrays.

Authors:  W I Mangrum; F Farassati; R Kadirvel; C P Kolbert; S Raghavakaimal; D Dai; Y H Ding; D Grill; V G Khurana; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

Review 7.  Abdominal Aortic Aneurysm: Evolving Controversies and Uncertainties.

Authors:  Davide Carino; Timur P Sarac; Bulat A Ziganshin; John A Elefteriades
Journal:  Int J Angiol       Date:  2018-05-29

8.  Presence of Borrelia burgdorferi sensu lato antibodies in the serum of patients with abdominal aortic aneurysms.

Authors:  I Hinterseher; G Gäbel; F Corvinus; C Lück; H D Saeger; H Bergert; G Tromp; H Kuivaniemi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-13       Impact factor: 3.267

9.  Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm.

Authors:  Catherine Rush; Moses Nyara; Joseph V Moxon; Alexandra Trollope; Bradford Cullen; Jonathan Golledge
Journal:  BMC Genomics       Date:  2009-07-06       Impact factor: 3.969

10.  Expression and Function of Ephrin-B1 and Its Cognate Receptor EphB2 in Human Abdominal Aortic Aneurysm.

Authors:  Aiji Sakamoto; Masaaki Kawashiri; Hatsue Ishibashi-Ueda; Yuka Sugamoto; Tsuyoshi Yoshimuta; Takeo Higashikata; Hitoshi Ogino; Hayato Tada; Tetsuo Konno; Kenshi Hayashi; Masakazu Yamagishi
Journal:  Int J Vasc Med       Date:  2012-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.